PACIRA BIOSCIENCES, INC. Costs Incurred, Asset Retirement Obligation Incurred
PACIRA BIOSCIENCES, INC. (PCRX) reported Costs Incurred, Asset Retirement Obligation Incurred of $166.00 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostsIncurredAssetRetirementObligationIncurred · last filed 2020-05-07
- PACIRA BIOSCIENCES, INC. costs incurred, asset retirement obligation incurred for the quarter ending 2020-03-31 was $166.00K, a 1409.09% increase year-over-year.
- PACIRA BIOSCIENCES, INC. costs incurred, asset retirement obligation incurred for the quarter ending 2019-12-31 was $58.00K, a 625.00% increase year-over-year.
- PACIRA BIOSCIENCES, INC. costs incurred, asset retirement obligation incurred for the quarter ending 2019-09-30 was $111.00K, a 1485.71% increase year-over-year.
- PACIRA BIOSCIENCES, INC. costs incurred, asset retirement obligation incurred for the quarter ending 2019-06-30 was $45.00K.
- PACIRA BIOSCIENCES, INC. costs incurred, asset retirement obligation incurred for fiscal 2019 was $225.00K, a 341.18% increase from fiscal 2018.
- PACIRA BIOSCIENCES, INC. costs incurred, asset retirement obligation incurred for fiscal 2018 was $51.00K, a 92.23% decline from fiscal 2017.
- PACIRA BIOSCIENCES, INC. costs incurred, asset retirement obligation incurred for fiscal 2017 was $656.00K.
| Period end | Costs Incurred, Asset Retirement Obligation Incurred 3 month | Costs Incurred, Asset Retirement Obligation Incurred 6 month | Costs Incurred, Asset Retirement Obligation Incurred 9 month | Costs Incurred, Asset Retirement Obligation Incurred 12 month |
|---|---|---|---|---|
| 2020-03-31 | $166.00K 10-Q · filed 2020-05-07 | $224.00K derived: sum of 2 quarters · filed 2020-05-07 | $335.00K derived: sum of 3 quarters · filed 2020-05-07 | $380.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $169.00K derived: sum of 2 quarters · filed 2020-02-21 | $214.00K derived: sum of 3 quarters · filed 2020-02-21 | $225.00K 10-K · filed 2020-02-21 |
| 2019-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $156.00K derived: sum of 2 quarters · filed 2019-11-08 | $167.00K 10-Q · filed 2019-11-08 | $175.00K derived: sum of 4 quarters · filed 2020-02-21 |
| 2019-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $56.00K 10-Q · filed 2019-08-08 | $64.00K derived: sum of 3 quarters · filed 2020-02-21 | $71.00K derived: sum of 4 quarters · filed 2020-02-21 |
| 2019-03-31 | $11.00K 10-Q · filed 2019-05-02 | $19.00K derived: sum of 2 quarters · filed 2020-02-21 | $26.00K derived: sum of 3 quarters · filed 2020-02-21 | $26.00K derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $15.00K derived: sum of 2 quarters · filed 2020-02-21 | $15.00K derived: sum of 3 quarters · filed 2020-02-21 | $51.00K 10-K · filed 2020-02-21 |
| 2018-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $7.00K derived: sum of 2 quarters · filed 2018-11-01 | $43.00K 10-Q · filed 2018-11-01 | $1.03M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $36.00K 10-Q · filed 2018-08-02 | $1.02M derived: sum of 3 quarters · filed 2020-02-21 | |
| 2018-03-31 | $36.00K 10-Q · filed 2018-05-03 | $1.02M derived: sum of 2 quarters · filed 2020-02-21 | ||
| 2017-12-31 | $986.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $656.00K 10-K · filed 2020-02-21 | ||
| 2017-09-30 | -$330.00K 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |